HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
Departamento
Queen Mary University of London
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de Queen Mary University of London (8)
2021
-
Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism
American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150
2019
-
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
The Lancet Neurology, Vol. 18, Núm. 9, pp. 845-856
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
-
The Big Data Sjögren consortium: A project for a new data science era
Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23
2018
-
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)
Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111
2017
-
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
Multiple Sclerosis, Vol. 23, Núm. 10, pp. 1367-1376
-
Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)
Diabetes, Obesity and Metabolism, Vol. 19, Núm. 7, pp. 1024-1031
2009
-
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228